AIM ImmunoTech prices $2.4M registered direct offering of 7.5M shares and warrants

AIM ImmunoTech Inc.

Offering of 7,519,351 shares at $0.325 per share; gross proceeds ~$2.4M before expenses.
Concurrent private placement of Common Warrants to purchase up to 15,038,702 shares at $0.325.
Warrants exercisable after stockholder approval, expire 5 years later; potential additional $4.9M.
Closing expected May 21, 2026; company expects at least $6M in stockholders' equity post-closing.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

AIM ImmunoTech Inc. entered into Purchase Agreement with institutional investors valued at approximately $2.4 million (effective 2026-05-20).

Action: entry
Agreement: equity purchase
Counterparty: institutional investors
Value: approximately $2.4 million
Effective: 2026-05-20

Exact text from the filing

On May 20, 2026, AIM ImmunoTech Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with institutional investors (the “Investors”), pursuant to which the Company agreed to issue and sell to such investors in a registered direct offering 7,519,351 shares (the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company, at an offering price of $0.325 per share (such registered direct offering, the “Registered Offering”).

View on SEC.gov

627 material agreements filed in the last 30 days. Browse all material agreements →

AIM ImmunoTech Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-024760

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.